Regeneron Pharmaceuticals (NSDQ:REGN) touted one-year results from a Phase III trial of its Eylea aflibercept injection in people with moderately severe to severe non-proliferative diabetic retinopathy. The primary endpoint of the two-year … [Read More...]
Listen to the recording of Reed Tech’s ‘Blanket No Change Certification webinar’ to learn about annual No Change Certification submission requirements for drug product listings and what steps are … [Read More...]
[Press Release] – WTWH Media and MassDevice.com announced today that Shacey Petrovic, president and CEO of Insulet (NSDQ:PODD), will be a featured keynote speaker at DeviceTalks Boston 2019. DeviceTalks Boston, which takes place on June 5-6, 2019, … [Read More...]
John Timberlake has been commercializing diabetes drugs and devices for 25 years. Over the course of his career, one theme has always stood out: if you want people to use your product, it has to be made with the end-user in mind. "It's really … [Read More...]
Medical device industry suppliers and outsourcers are helping to enable the latest drug-delivery tech. Drug-eluting technologies are moving beyond stents, thanks in part to the development of polymeric hydrogels engineered to respond to a range of … [Read More...]
In the era of personalized medicine, cancer patients will often have their tumors biopsied and analyzed as doctors hunt for mutations that are driving the patient's condition. For some forms of cancer, doctors can recommend therapies that target … [Read More...]
Much of Dr. Todd Hobbs' life has centered around diabetes - he was diagnosed with Type I diabetes roughly 30 years ago and now he is the father of a child with diabetes. At his Kentucky-based primary care practice, he took on diabetic patients and … [Read More...]
Dr. Ron Cohen isn't easily deterred. The physician-turned-executive has spent decades in the biotech industry and weathered a number of setbacks – he learned in his early years at the now-defunct Advanced Tissue Sciences that to succeed, he needed … [Read More...]
Shares in Oldwick, N.J.-based Provention Bio began trading today following the close of its $64 million initial public offering last week. The biopharmaceutical company, lead by co-founder & CEO Ashleigh Palmer, is developing a number of … [Read More...]
People living with pancreatic cancer find themselves facing devastating odds - the five-year survival rate is in the single digits, according to the American Cancer Rate. Pursuing treatment often means dealing with the side effects of systemic … [Read More...]
Large pharmaceutical companies dominate the dry eye disease space - Allergan (NYSE:AGN) rakes in more than a billion dollars every year for its Restasis eye drops. Eight-person Oyster Point Pharma wants in on that market. But it's betting on a … [Read More...]
Transmitted by the same mosquitoes that spread Zika virus and dengue fever, the chikungunya virus is named for an African word meaning "to become contorted." People infected with the alphavirus are afflicted with lasting joint pain that causes their … [Read More...]
When Al Robichaud got his start as a medicinal chemist in 1991, he knew that discovering and developing drugs meant shouldering some level of risk. But around 2011, it became clear that the process for developing brain drugs was too costly and … [Read More...]
From discovery to commercial launch, drug development often takes years. New tools available to the industry, like the use of biomarkers and patient-reported outcomes, promise to help inform and speed up the process. "Being able to pick out the … [Read More...]
For decades, nurses have sent drugs surging through a patient's body using the power of the circulatory system. Catheters deliver medications destined to travel through a person's veins – but it doesn't always turn out that way. Sometimes, leaky … [Read More...]
Before she was Foundation Medicine's (NSDQ:FMI) chief business executive, Melanie Nallicheri was as an advisor to an ongoing project at the Cleveland Clinic, where she was witness to the power of personalized cancer treatment. Her team was caring … [Read More...]
In the early days of auto-injectors, people learned how to use their devices by practicing with the skin of an orange, according to Noble's research manager, Joe Reynolds. "The rationale was 'Well, let's teach patients how to penetrate a skin-like … [Read More...]
While pain medicine specialist Dr. Pamela Palmer was working on the West Coast in the early 2000's, she noticed something peculiar was happening to patients undergoing surgery - many who survived their procedures were dying of opioid overdoses as a … [Read More...]
Companies have tried for decades to deliver protein-based drugs orally. Can Mir Imran and his company’s robotic pill succeed where so many have failed? Mir Imran has been building medical device companies for 40 years. Perhaps known best for his … [Read More...]
To control an asthma patient's symptoms, doctors will prescribe an inhaler to stop symptoms from cropping up and a rescue inhaler to be used if patients find themselves in the middle of an asthma attack. "But if your rescue inhaler doesn't give … [Read More...]
Recognizing that digital technology is here to stay in the business of healthcare, pharmaceutical companies have not shied away from collaborating with the folks in Silicon Valley. Sanofi (NYSE:SNY), for instance, has dove in feet first, striking … [Read More...]
Amgen (NSDQ:AMGN) won FDA approval this week for its once-monthly Aimovig injection designed to prevent the onset of migraines in adults. The drug is the first of its kind - a molecule that blocks the receptor for a protein that is linked to … [Read More...]
PolarityTE wants to eliminate skin grafts with its platform of regenerative technology. The Utah-based biotech is still new to the industry, but co-founders Denver Lough and Ned Swanson are betting that their company can take on the clinical standard … [Read More...]
In its latest financial results, Cambridge, Mass.-based Vericel (NSDQ:VCEL) saw sales climb 60% for its permanent skin-replacement product, Epicel, designed for patients with severe burns. Sales for its autologous cellular scaffold, Maci, were up 20% … [Read More...]
Thousands of cancer patients have been treated with immune checkpoint inhibitors since the first of its kind was approved in 2011. The product is designed to block the production of proteins that prevent the body's immune system from acting in the … [Read More...]
After seven people died in 2013 from serious allergic reactions to Omontys, an injectable anemia drug marketed by Takeda Pharmaceutical (TYO:4502) and Affymax, the companies recalled the product and regulators launched an investigation to find out … [Read More...]
Kevin Sayer sold his first glucose sensor in 1994. More than twenty years later, the chief executive of Dexcom (NSDQ:DXCM) still believes that glucose-monitoring technology can transform the way patients manage their diabetes. This week, Dexcom … [Read More...]
In some instances, as many as 30% of patients need repeat surgeries get rid of cancerous cells initially left behind. The team from Lumicell wants to change that — and improve outcomes for cancer patients. [Image by MDO art director Matthew … [Read More...]
Despite growing attention from lawmakers and doctors, the opioid crisis is not slowing up in the U.S. A new report published last week by the Centers for Disease Control and Prevention showed that emergency room visits for opioid overdoses jumped 30% … [Read More...]
There are millions of Americans with Type II diabetes and many of them take multiple daily injections of insulin, using two injection pens - one for mealtime insulin and one for insulin throughout the day. But studies have found that people with Type … [Read More...]
Paclitaxel revolutionized cancer treatment when it was first used as a chemotherapeutic in the 1990s. But although the product is a powerful cancer killer, patients taking systemic doses of paclitaxel have to endure side effects such as peripheral … [Read More...]
More than two decades after it was first synthesized in a lab, omadacycline is finally being reviewed by the FDA for its potential as a broad-spectrum antibiotic. It's a long-awaited milestone for Dr. Evan Loh, who serves as president, COO and CMO … [Read More...]
Nobody likes to be on the receiving end of a shot. Studies have found that needle anxiety keeps people from getting important medications, like the flu vaccine, and can even stop people from taking self-injected drugs to manage chronic … [Read More...]
It often starts in the doctor's office or the emergency room. A patient has broken their leg and will be in pain for weeks. Another patient has had back surgery and is on their way home, but it will take time before they're fully recovered. A third … [Read More...]
In the past decade, new innovations and well-funded research have heralded in the era of immunotherapy. The pace of change within the field has amazed Peter Hoang, the chief executive of a Jacksonville, Fl.-based company working to develop … [Read More...]
The "smart pill" market is expected to nearly quadruple in value to $3 billion by 2025, according to Grand View Research. Driving this growth is an increasing demand for minimally-invasive procedures, as well as better patient monitoring … [Read More...]
Shankar Musunuri has spent time in both the pharmaceutical world and the biotech arena - after 15 years at Pfizer (NYSE:PFE), he went on to launch several biotech start-ups. As co-founder, chairman & chief executive of Ocugen, he is looking to … [Read More...]
At the 124,000-square foot Cambridge headquarters of Mass Innovation Labs, co-founder & CEO Amrit Chaudhuri points to a cluster of tables and identifies them one by one: This startup went public and did a massive deal with Merck (NYSE:MRK), he … [Read More...]
When Jeff Dachis was diagnosed with Type I diabetes four years ago, he remembers leaving the doctor's office with a sinking feeling in his chest. "I had about six minutes with a nurse practitioner and was given an insulin pen and a prescription … [Read More...]
Mike Hooven is no stranger to the medical device industry - he has spent the last 30 years launching companies and developing technologies for a variety of clinical applications. So when he ventured into drug delivery, he knew that he needed to find … [Read More...]
Although antibodies have gained plenty of ground in recent years as vehicles for cancer therapies, Aridis Pharmaceuticals wants to use them as nature intended - to fight infection. "These are human monoclonal antibodies being investigated as … [Read More...]
Denis Corin has spent the last 13 years in the biopharmaceutical industry watching and learning from scientists and companies that fail. "I've seen so many promising and innovative young technologies really struggle along or die on the vine … [Read More...]
Formed just two years ago, pharma startup Pneuma Respiratory is developing a digital inhaler that it touts as the first of its kind. The company is looking to bring its technology to the more than 40 million people who suffer from asthma or … [Read More...]
Millions of people around the world are losing their hearing thanks to inner ear disorders and the pharmaceutical industry has spent years working to develop therapeutics to help address this patient population. But Jeff Borenstein, lead scientist … [Read More...]
For nearly a decade, Michele Barbour and her team of researchers at the University of Bristol have been developing controlled-release salts of a commonly-used chemical called chlorhexidine. Barbour believed her technology had enormous potential - so … [Read More...]
At the 7th annual Partnership Opportunities in Drug Delivery event, presented by The Conference Forum, device companies gathered to tout their drug-delivery technologies and learn from each other's mistakes and successes. Among them were … [Read More...]
As companies race to develop the first fully-automated insulin delivery system, a group of tech-savvy patients are hacking their own artificial pancreas systems. And industry is just starting to take notice of this highly motivated grassroots … [Read More...]
Just last week, OptiScan Biomedical announced that its OptiScanner 5000 glucose monitoring system won 510(k) clearance for use in surgical intensive care units. The regulatory win was supported by eight rigorous clinical trials, CEO Peter Rule … [Read More...]
Ned Swanson and Denver Lough were plastic surgery residents at Johns Hopkins when they made a choice that would change the course of their lives - they decided to drop out and start a business. Lough had a technology that they thought could help … [Read More...]
With Gilead Sciences (NSDQ:GILD) and Novartis (NYSE:NVS) leading the way, cell therapies are moving on to the market and into the clinics for patients that have no other option. Companies making CAR-T therapies use a patient's own cells to … [Read More...]
When Harry Travis first met Neil Euliano and learned about his medication adherence technology, the pharmaceutical industry was beginning to usher in the age of pricey drugs with Hepatitis C therapies that hit the market at prices like $500 or $1,000 … [Read More...]
Designing devices centered around patients is a goal espoused by nearly all device companies nowadays, as they aim to make products that people want to use and can incorporate into their everyday lives. Underscoring those products is often years of … [Read More...]
Kevin Sayer describes Dexcom's (NSDQ:DXCM) history as punctuated by "firsts" - its continuous glucose meter was the first to connect to a phone. Last year, the company's tool became the first approved by the FDA as one from which a patient with … [Read More...]
Shacey Petrovic spent nearly a decade trying to convince her diabetic father to switch to an insulin pump, rather than inject himself multiple times each day. But he was wary of the tubing and other challenges that come with constantly wearing a … [Read More...]
Takeda Pharmaceutical (TYO:4502) has been on a partnership spree lately, inking at least 65 collaborations and deals in the last 18 months. Fueling those agreements is a fundamental belief that to reinvigorate the pharmaceutical industry, access … [Read More...]
Shares in Cambridge-based Vericel Corp (NSDQ:VCEL) surged last year after the FDA approved its bioresorbable scaffold for cartilage repair. The product, Maci, is the first FDA-approved implant to use healthy cartilage tissue from a patient's own … [Read More...]
As a dentist, Mark Hochman gave countless injections to his patients and watched as many of them would cringe from pain. Frustrated with a technology that he said hasn't improved in decades, he decided to take a different approach to the common … [Read More...]
Major players in the medical device realm are in a heated race to develop the first artificial pancreas to help patients with diabetes manage the chronic condition. Just last year, Medtronic (NYSE:MDT) won FDA approval for its MiniMed 670G … [Read More...]
David Lee began his path to CEO of Lumicell in 1999, when his wife was diagnosed with cancer. She passed away in 2003, while Lee was working in the semiconductor industry. He decided it was time for a career change. More than a decade later, Lee … [Read More...]
Senseonics (NYSE:SENS) this week announced that it partnered with Geo-Med to provide access to the Eversense continuous glucose monitor to more than 9 million veterans and U.S. government staff. The company's Eversense device is the first CGM … [Read More...]
The FDA announced this week that it established Tandem Diabetes Care's (NSDQ:TNDM) t:slim X2 insulin pump as the first in a new category of devices called 'Alternate Controller Enabled Infusion Pumps' or ACE pumps. The newly-approved indication … [Read More...]
The FDA has given Ocugen orphan drug status for a gene therapy designed to treat NR2E3 mutation-associated retinal degenerative disease. The Malvern, Penn.-based company's OCU400 product includes an adeno-associated virum serotype 5 capsid that … [Read More...]
Inovio Pharmaceuticals (NSDQ:INO) said today that it priced an offering of $65 million of 6.5% convertible senior notes due 2024. The Plymouth Meeting, Penn.-based company also gave initial purchasers a 13-day option to buy up to an additional $20 … [Read More...]
An FDA advisory committee has voted to support Johnson & Johnson's (NYSE:JNJ) Spravato esketamine nasal spray product as a therapy for adults living with treatment-resistant depression. J&J's Janssen touted that if the U.S. regulatory … [Read More...]
scPharmaceuticals' (NSDQ:SCPH) has signed a development agreement to incorporate West Pharmaceutical Services' (NYSE:WST) SmartDose drug delivery system with Furoscix, a drug that scPharmaceuticals developed to treat edema in heart failure … [Read More...]
Mylan (NSDQ:MYL) today announced the launch of its Wixela Inhub product, a generic for GlaxoSmithKline's (NYSE:GSK) Advair Diskus device, for people with asthma or chronic obstructive pulmonary disease. The company touted that its device's list … [Read More...]
A former PixarBio (OTC:PXRB) employee pleaded guilty last Friday to charges of fraud and obstruction, according to a recent report from the Boston Business Journal. The employee, Jay Herod, was accused of making false statements to the SEC and … [Read More...]
Regeneron Pharmaceuticals (NSDQ:REGN) touted one-year results from a Phase III trial of its Eylea aflibercept injection in people with moderately severe to severe non-proliferative diabetic retinopathy. The primary endpoint of the two-year Panorama trial is the proportion of patients who experience a two-step or greater improvement in the ‘diabetic retinopathy severity scale.’ Of the 133 people […]
Pulmatrix (NSDQ:PULM) said today that the FDA approved a Phase II trial of the company’s inhaled formulation of the anti-fungal drug itraconazole for the treatment of allergic bronchopulmonary aspergillosis in people with asthma. The Lexington, Mass.-based company plans to kick off the trial in the first half of 2019, with top-line data expected in the second […]
The FDA this week published a finalized guidance document for companies developing new buprenorphine depot products for the treatment of opioid use disorder. The agency is hoping to boost the development of modified-release buprenorphine products, like drug-eluting implants. In the document, the FDA detailed the studies needed to support approval for these products through the 505(b)(2) […]
Audion Therapeutics touted positive results yesterday from a Phase I trial of the company’s hearing loss drug. In 15 people with mild to moderate sensorineural hearing loss, Audion tested the safety and tolerability of its LY3056480 mediated Notch inhibitor. The drug is designed to regenerate the inner ear sensory hair cells that are lost over […]
Amid concerns about a potential link between paclitaxel devices and heightened long-term mortality rates, Medtronic (NYSE:MDT) and other device-makers doubled down on their products’ safety at this year’s Leipzig Interventional Course in Germany. Medtronic presented a patient-level survival analysis that included 1,837 patients enrolled in its In.Pact Admiral clinical program. The analysis assessed all-cause mortality across […]
Drug Delivery Business News
@DrugDeliveryNow
LinkedIn